WENTWORTH KORY JAMES 4

What Happened Kory James Wentworth, CFO of Entrada Therapeutics, reported sales of company stock in two transactions. On 2026-03-09 he sold 5,089 shares at a reported weighted-average price of $13.00 for $66,163, and on 2026-03-10 he sold 11,388 shares at a reported weighted-average price of $13.02 for $148,216 — total 16,477 shares and roughly $214,379 in proceeds. These were disposals (sales), not purchases.

Key Details

• Transaction dates: March 9, 2026 (5,089 shares @ $13.00, $66,163) and March 10, 2026 (11,388 shares @ $13.02, $148,216).
• Aggregate sold: 16,477 shares for ~$214,379. Method listed as open market or private sale (Form 4 code S).
• Footnotes: Trades were executed under a Rule 10b5-1 trading plan adopted March 6, 2025 (F1). Price reporting uses weighted averages; March 9 sales ranged $12.95–$13.14 (F2) and March 10 sales ranged $12.95–$13.20 (F3). The filer can provide a per-price breakdown on request.
• Shares owned after the transactions: Not disclosed in the excerpt of this filing.
• Filing: Form 4 filed with the SEC on March 11, 2026 (no late-filing flag shown in the provided data).

Context Sales under a 10b5-1 plan are pre‑planned and are commonly used by insiders to regularly liquidate holdings; they do not necessarily signal a change in company outlook. For retail investors, purchases are generally more informative about insider conviction; this filing documents routine disposals by the CFO totaling about $214k.